For research use only. Not for therapeutic Use.
JNc-440 is a potent antihypertensive agent. JNc-440 can enhance the interaction of TRPV4 and Ca2+-activated potassium channel 3 (KCa2.3) in endothelial cells. JNc-440 can also enhance vasodilation, and exerted antihypertensive effects in mice[1].
JNc-440 (1 mg/kg; IV; single dosage) improves endothelium-dependent relaxation in small resistance arteries and to lower blood pressure[1].
| Catalog Number | I043479 |
| CAS Number | 1119503-63-7 |
| Synonyms | N-[3-[(2,2-diphenylacetyl)amino]propyl]-4-oxo-3H-quinazoline-2-carboxamide |
| Molecular Formula | C26H24N4O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H24N4O3/c31-24-20-14-7-8-15-21(20)29-23(30-24)26(33)28-17-9-16-27-25(32)22(18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-8,10-15,22H,9,16-17H2,(H,27,32)(H,28,33)(H,29,30,31) |
| InChIKey | VMRVWMQQRPXUQU-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NCCCNC(=O)C3=NC4=CC=CC=C4C(=O)N3 |
| Reference | [1]. He D, et al. Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction. EMBO Mol Med. 2017 Nov;9(11):1491-1503. |
